A1C Almanac

Main Page

Berberine at the Crossroads of Metabolic Health and Longevity: From “Nature’s Ozempic” Hype to Translational Opportunities in Preventive Medicine

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Keywords: , , , ,

Introduction

Berberine is an isoquinoline alkaloid isolated from various medicinal plants, including species of the genera Berberis and Coptis, with a long history of use in traditional Chinese and Ayurvedic medicine, particularly for the management of infections and gastrointestinal disorders. Over the last decade, berberine has gained renewed attention within the wellness and biohacking communities, where it is frequently promoted as “nature’s Ozempic” for weight reduction and glycaemic control. Beyond such popularized narratives, accumulating preclinical and translational data indicate that berberine modulates key nutrient‑sensing pathways, including AMP‑activated protein kinase (AMPK), sirtuin 1 (SIRT1), and mechanistic target of rapamycin (mTOR), thereby positioning it as a candidate caloric‑restriction mimetic with potential relevance for metabolic disease prevention and healthy longevity.

Concurrently, the global prevalence of obesity, metabolic syndrome, and type 2 diabetes continues to increase despite broad access to established pharmacotherapies such as metformin, statins, and, more recently, glucagon‑like peptide‑1 (GLP‑1) receptor agonists. This epidemiological context has intensified interest in low‑cost, orally available interventions that can complement conventional drugs and structured lifestyle modification, particularly among younger, health‑conscious individuals who display early metabolic dysfunction but do not yet fulfil diagnostic criteria for overt disease. Within this landscape, berberine is being evaluated in randomized controlled trials targeting dyslipidaemia, insulin resistance, and broader cardiometabolic risk; however, important uncertainties remain regarding the magnitude and durability of its effects, optimal dosing strategies, treatment duration, long‑term safety, and potential drug–nutrient interactions.

The present article aims to synthesize and critically appraise current evidence on berberine through two complementary lenses. First, we consider its role as a metabolic therapeutic in the context of obesity, dyslipidaemia, and prediabetes. Second, we examine cellular and systems‑level mechanisms relevant to health span, with a focus on AMPK–SIRT1–mTOR signalling, autophagy, and caloric‑restriction mimetic properties. By integrating these perspectives, our goal is to provide clinicians, health‑technology teams, and biohackers with a pragmatic, prevention‑oriented framework for evaluating the potential place of berberine, if any, within data-driven, personalized models of cardiometabolic and longevity-focused care.

Berberine and Metabolic Disease: What do The Trials Show

Meta‑analyses of randomized placebo‑controlled trials indicate that berberine exerts clinically relevant effects on multiple components of the metabolic syndrome profile, with short‑term use generally well tolerated. A 2025 systematic review of 12 RCTs in adults with metabolic syndrome (n=889) reported significant reductions in triglycerides, fasting plasma glucose, and waist circumference, with a pooled weighted mean difference (WMD) for triglycerides of approximately −0.37 mmol/L (95% CI −0.56 to −0.18), along with improvements in total and LDL‑cholesterol. In that analysis, six RCTs (n=578) demonstrated a WMD in fasting plasma glucose of −0.52 mmol/L (95% CI −0.85 to −0.18), supporting a modest glucose‑lowering effect in individuals with clustered cardiometabolic risk factors. Earlier meta‑analyses that pooled trials in type 2 diabetes and related metabolic disorders similarly reported improvements in HOMA‑IR, fasting plasma glucose, 2‑hour post‑prandial glucose, HbA1c, BMI, and lipid parameters, consistent with enhanced insulin sensitivity and more favourable body‑weight dynamics [1,2,3].

Duration of therapy appears to modulate the magnitude of lipid responses. In the 2025 metabolic‑syndrome meta‑analysis, meta‑regression and subgroup analyses suggested that interventions of ≤90 days yielded greater improvements in HDL‑C and LDL‑C than longer treatment periods, with attenuation of effect estimates beyond roughly 3–4 months. These findings align with earlier work in hyperlipidaemia, where berberine monotherapy or combination therapy significantly reduced total cholesterol and LDL‑C and increased HDL‑C compared with placebo, although heterogeneity and variable background therapies complicate cross‑study comparison. From a safety perspective, the 2025 analysis found no significant difference in overall adverse events between berberine and placebo, with gastrointestinal symptoms representing the most frequent, typically mild, side‑effects [1,4,5].

Berberine has been evaluated both as a stand‑alone agent and as an adjunct to standard pharmacotherapy. In patients with type 2 diabetes, a large systematic review and meta‑analysis of 46 RCTs reported that berberine, alone or combined with conventional agents, reduced HbA1c by approximately 0.7 percentage points and improved fasting and 2‑hour post‑prandial glucose, HOMA‑IR, BMI, and lipid metrics, with an overall safety profile comparable to controls. Comparative analyses suggest that berberine monotherapy achieves glycaemic control similar to metformin in some trials, while the combination of berberine plus metformin yields superior reductions in HbA1c and 2‑hour glucose versus metformin alone; however, most of these studies are small and methodologically limited, warranting cautious interpretation. Adjunctive use with statins has likewise demonstrated additive lipid‑lowering effects in hyperlipidaemic patients, again in the context of relatively short‑duration, moderate‑quality trials [2,4,6,7].

More recently, attention has shifted toward preventive and body‑composition endpoints in individuals without diabetes but with obesity or visceral adiposity. An ongoing and recently reported randomized clinical trial in diabetes‑free adults with obesity is assessing berberine’s impact on visceral adipose tissue and liver fat content, reflecting growing interest in its use earlier in the metabolic disease continuum. Parallel RCTs and registrational studies are exploring berberine for broader cardiometabolic risk modification, including in populations at high risk for diabetes and cardiovascular disease, but robust data on hard outcomes (incident diabetes, cardiovascular events, or mortality) are not yet available. Collectively, current trials support berberine as a modestly effective, generally safe adjunct for improving surrogate metabolic endpoints over weeks to a few months, while underscoring the need for larger, longer‑term, rigorously designed studies to define its true role in metabolic disease prevention and management [1,2,3,8,9,10,11,12].

Mechanistic Pathways: AMPK, SIRT1, mTOR and Autophagy

At the cellular level, berberine exerts pleiotropic actions on energy‑sensing and stress‑response pathways, with AMP‑activated protein kinase (AMPK) representing a central node. In multiple cell systems and rodent models, berberine rapidly increases AMPK phosphorylation, in part via inhibition of mitochondrial respiratory chain complex I, leading to a rise in the AMP/ATP ratio and consequent activation of AMPK signalling, analogous to the mechanism described for metformin. Downstream of AMPK, berberine enhances glucose uptake in skeletal muscle and liver, promotes fatty‑acid oxidation, suppresses lipogenesis through inhibition and phosphorylation of SREBP‑1c, and reduces hepatic gluconeogenesis, mechanistically aligning with observed improvements in fasting glucose, insulin sensitivity, and lipid profiles in clinical trials. Berberine also modulates adipokine secretion and inflammatory signalling, and influences the gut microbiome and bile‑acid pool composition, which may further contribute to improved insulin sensitivity and metabolic homeostasis, although human data on these latter pathways remain comparatively limited [13,14,15,16,17,18,19].

Figure 1. Metabolic Pathways of Oral Berberine [14]

Berberine additionally interfaces with sirtuin 1 (SIRT1) and mechanistic target of rapamycin (mTOR), two key regulators of longevity‑related biology. Experimental work in macrophages demonstrates that berberine activates SIRT1 via the NAD⁺ synthesis pathway, promoting formation of a SIRT1–TFEB complex, deacetylation of the transcription factor EB (TFEB), and its nuclear translocation, thereby up‑regulating autophagy and reducing apoptosis. In parallel, berberine modulates PI3K/AKT/mTOR signalling in atherosclerosis models, improving serum lipid levels, attenuating carotid intimal hyperplasia, and altering expression of autophagy‑related proteins, consistent with mTOR‑linked regulation of autophagic flux and plaque biology. In neuronal and other tissues, berberine has been reported to activate AMPK/SIRT1/PGC‑1α and related stress‑response pathways, enhancing mitochondrial biogenesis, antioxidant defences, and autophagy, and delaying neurodegenerative phenotypes in preclinical models, findings hat support its classification as a candidate caloric‑restriction mimetic acting on nutrient‑sensing and proteostasis networks central to health span [14,16,20,21,22,23].

Berberine as a Caloric-Restriction Mimetic and Longevity Tool

Caloric‑restriction mimetics (CRMs) are pharmacological or nutraceutical agents that recapitulate key cellular effects of energy restriction, such as enhanced autophagy, improved mitochondrial biogenesis, reduced oxidative stress, and dampened inflammatory signalling without necessitating a sustained reduction in caloric intake. Berberine has emerged as a candidate CRM because it convergently activates AMPK, up‑regulates SIRT1 and downstream PGC‑1α, and inhibits mTORC1, thereby engaging the same nutrient‑sensing pathways that mediate lifespan extension in multiple model organisms under caloric restriction. In preclinical studies, these actions translate into improved mitochondrial function, enhanced autophagic flux, and reduced markers of cellular senescence and inflammaging across metabolic, cardiovascular, and neurodegenerative disease models [14,16,20,21,22,24].

In ageing rodent models, chronic berberine administration has been shown to improve cognitive performance, motor function, and muscle endurance, effects that are mechanistically linked to AMPK/SIRT1/PGC‑1α activation and improved mitochondrial quality control. For example, experimental work in neurodegeneration models demonstrates that berberine enhances mitochondrial biogenesis, increases antioxidant enzyme activity, reduces neuroinflammation, and promotes autophagy‑mediated clearance of misfolded proteins, collectively delaying the onset or progression of neurodegenerative phenotypes. In vascular and macrophage systems, berberine‑induced SIRT1 activation and TFEB deacetylation augment autophagy and limit apoptosis, while suppression of PI3K/AKT/mTOR signalling in atherosclerosis models leads to smaller, more stable plaques, echoing caloric‑restriction–like effects on vascular ageing. These multi‑tissue benefits, coupled with favourable metabolic remodelling, underpin the positioning of berberine as a CRM acting on core longevity pathways [14,16,20,21,22,23].

In humans, evidence for berberine as a longevity tool remains indirect and largely inferred from improvements in intermediate cardiometabolic and body‑composition endpoints rather than from hard ageing outcomes such as incident cardiovascular events, frailty, disability, or mortality. Randomized trials and meta‑analyses in metabolic syndrome and type 2 diabetes consistently show modest reductions in fasting plasma glucose, HbA1c, triglycerides, LDL‑cholesterol, BMI, and waist circumference, consistent with reduced cardiometabolic risk and potentially slower vascular and metabolic ageing if effects are durable over time. More recently, studies in diabetes‑free individuals with obesity or increased visceral adiposity have reported reductions in visceral fat and liver fat content with berberine treatment, suggesting an early‑intervention role in remodelling central adiposity and ectopic fat deposition, key drivers of cardiometabolic and possibly biological ageing trajectories [1,2,3,8,9].

However, no long‑duration, event‑driven clinical trials have yet demonstrated that berberine meaningfully extends health span or lifespan in humans, nor are there robust longitudinal data linking berberine‑induced changes in nutrient‑sensing biomarkers (e.g. AMPK activity, SIRT1‑related signatures, autophagy markers) to delayed ageing phenotypes. Current human data therefore support berberine as a promising metabolic and mechanistic proxy for caloric restriction, particularly in terms of AMPK–SIRT1–mTOR engagement and body‑composition improvements, but its status as a true longevity intervention remains investigational and hypothesis‑generating. Within this context, any deployment of berberine as a “longevity tool” is best framed as an adjunct to, rather than a replacement for, foundational lifestyle strategies (nutritional quality, appropriately dosed caloric intake, physical activity, sleep, and circadian alignment) and established pharmacotherapies with outcome‑level evidence, while ongoing and future trials clarify its role in human health span optimisation [1,2,5,8,9,14,16,21,].

Safety, Tolerability, and Practical Considerations

Across randomized controlled trials and systematic reviews, berberine has demonstrated a generally favourable short‑term safety profile, with adverse events predominantly involving the gastrointestinal tract. The most frequently reported symptoms include constipation, diarrhea, abdominal discomfort, and nausea, which are usually mild to moderate in intensity and rarely necessitate treatment discontinuation. Serious adverse events have not differed significantly between berberine and placebo in studies of 8–24 weeks’ duration, although the interpretability of these findings is constrained by modest sample sizes, heterogeneous populations, and relatively brief follow‑up periods. Data on rare events, organ‑specific toxicity, and long‑term outcomes remain limited, underscoring the need for larger and longer trials before firm safety conclusions can be drawn, particularly for longevity‑oriented, multi‑year use [1,9, 26,27].

From a pharmacokinetic and drug‑interaction standpoint, berberine presents several important practical considerations. Experimental and clinical pharmacology studies indicate that berberine can inhibit P‑glycoprotein (P‑gp) and modulate cytochrome P450 activity, with implications for the absorption and clearance of co‑administered medications. This raises particular concern for drugs with a narrow therapeutic window or those heavily dependent on P‑gp or specific CYP isoenzymes, including certain antiarrhythmics, anticoagulants, calcineurin inhibitors, and other cardiovascular or immunosuppressive agents. In individuals with polypharmacy, careful medication reconciliation, monitoring of relevant drug levels (where applicable), and vigilance for toxicity or loss of efficacy are therefore warranted when initiating or up‑titrating berberine [28,29].

In clinical research and practice, berberine has typically been administered at total daily doses between 500 and 1500 mg, divided into two or three doses taken with meals, over treatment periods ranging from approximately 8 to 24 weeks. This dosing range appears to balance metabolic efficacy with tolerability in the short term, but there is no consensus “optimal” dose for health span or longevity indications. Key unanswered questions include the safety and efficacy of chronic use beyond six months, the risk–benefit profile in patients with hepatic or renal impairment, and the appropriateness of berberine in pregnancy and lactation, where data are currently insufficient to support routine use. Until more robust evidence is available, cautious, time‑limited prescribing with clear review points is advisable, particularly outside formal trial settings [1,26,27,30,31,32,33].

Within digital‑health and AI‑enabled care models, berberine lends itself to structured, monitored N=1 experimentation rather than unstructured supplementation. Integrating berberine use with continuous glucose monitoring, periodic lipid and liver‑function testing, and longitudinal anthropometric and symptom tracking can help identify individual responder patterns, detect emerging adverse effects, and inform decisions around dose adjustment or discontinuation. Embedding explicit contraindications (e.g. pregnancy, significant hepatic dysfunction, high‑risk drug–drug interactions) and mandatory follow‑up intervals into digital protocols or decision‑support systems may mitigate safety risks while enabling data‑driven personalization. In this context, berberine is best positioned as a monitored adjunct layered on top of foundational lifestyle interventions, rather than as a stand‑alone or untracked biohacking tool [1,26,27,30,31,33].

Future Directions for AI-Enabled Preventive Care

AI‑enabled preventive‑care ecosystems provide a natural testbed for integrating berberine as a precision nutraceutical within structured, longitudinal cardiometabolic programs. In such models, high‑frequency real‑world data streams such as continuous glucose monitoring (CGM), serial lipidomics, anthropometric trajectories, physical‑activity and dietary logs, and patient‑reported outcomes can be ingested into AI platforms to identify responder phenotypes, characterize dose–response relationships, and detect early signals of intolerance or drug–nutrient interactions. Experience from AI‑driven metabolic programs and digital‑twin–enabled precision nutrition in type 2 diabetes suggests that this approach can meaningfully improve glycaemic control and reduce medication burden, illustrating how similar infrastructures could be adapted to systematically evaluate berberine and other nutraceuticals rather than relying on anecdotal biohacking practices [,34,35,36,37,38].

Embedding evidence‑based guardrails into algorithmic decision‑support will be critical to avoid uncritical adoption driven by social‑media trends. Current reviews of berberine’s efficacy and safety for metabolic syndrome highlight both its modest benefits and the limitations of short‑term RCTs, underscoring the need for clear exclusion criteria (e.g. pregnancy, significant hepatic impairment, high‑risk polypharmacy), predefined treatment windows, and mandatory laboratory and clinical follow‑up when it is deployed at scale. AI systems can operationalize these safeguards by automatically flagging contraindications, surfacing drug‑interaction risks (via P‑glycoprotein and CYP modulation), and prompting repeat testing of glycaemic, lipid, and liver‑function markers at appropriate intervals, thereby aligning real‑world use with best‑available evidence [1,8,26,27,28].

Looking ahead, mechanistically informed digital‑twin frameworks offer a path to more sophisticated personalization of berberine within cardiometabolic and longevity‑oriented care. Digital twins, virtual replicas of an individual that combine mechanistic models with multi‑omic, CGM, anthropometric, and microbiome data have already shown promise in predicting glycaemic responses and chronic kidney disease risk in people with type 2 diabetes, and are being proposed as a paradigm for cardiometabolic‑based chronic disease management. Incorporating AMPK–SIRT1–mTOR pathway dynamics and body‑composition trajectories into such models could help determine when berberine is best used as a short‑term metabolic intervention, a cyclical caloric‑restriction mimetic, or an adjunct during GLP‑1 “step‑down” phases, and could support rational comparison with other pathway‑targeting nutraceuticals such as spermidine and resveratrol. In this vision, AI‑driven digital twins would not simply recommend “supplement stacks,” but would iteratively simulate and test intervention scenarios against individualized risk landscapes, moving berberine use from empiric biohacking toward rigorously monitored, data‑driven preventive care [34,37,39,40,41,42].

Conclusion

Berberine occupies an important conceptual space at the interface of  metabolic therapeutics and longevity science. Randomized controlled trials and meta‑analyses consistently demonstrate modest but clinically relevant improvements xin glycaemic indices, lipid parameters, and anthropometric measures, while preclinical work supports convergent modulation of AMPK–SIRT1–mTOR signalling and autophagy pathways. Taken together, these data support framing berberine as a promising adjunct for metabolic risk reduction and a candidate caloric‑restriction mimetic, rather than as a validated substitute for glucagon‑like peptide‑1 receptor agonists or other cornerstone therapies with robust outcome‑level evidence.

From a clinical and AI‑enabled health‑technology perspective, the priority is to embed berberine, where used within structured, monitored prevention programs that prioritize lifestyle foundations (nutrition, physical activity, sleep, circadian alignment), rigorous phenotyping, and systematic monitoring of safety and potential drug–nutrient interactions. This includes careful attention to patient selection, clear treatment goals, and predefined metrics for continuation or deprescribing, ideally supported by integrated data streams such as continuous glucose monitoring, lipid panels, and body‑composition assessments. As higher‑quality, longer‑duration randomized trials and real‑world datasets emerge, including studies in diabetes-free but metabolically high=risk populations, it should become clearer whether berberine can transition from a predominantly “biohacking” intervention to a standardised, evidence‑based component of longevity‑oriented metabolic care.

Reference

  1. Liu D, Zhao H, Zhang Y, Hu J, Xu H. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Frontiers in Pharmacology. 2025 Jul 16;16.
  2. Guo J, Chen H, Zhang X, Lou W, Zhang P, Qiu Y, et al. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxidative Medicine and Cellular Longevity [Internet]. 2021;2021:2074610. Available from: https://pubmed.ncbi.nlm.nih.gov/34956436/
  3. Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, et al. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Frontiers in Pharmacology. 2021 Apr 26;12.
  4. Zhang LS, Zhang JH, Feng R, Jin XY, Yang FW, Ji ZC, et al. Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. The American Journal of Chinese Medicine. 2019 Jan;47(04):751–67.
  5. Och A, Och M, Nowak R, Podgórska D, Podgórski R. Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease. Molecules (Basel, Switzerland) [Internet]. 2022 Feb 17;27(4):1351. Available from: https://pubmed.ncbi.nlm.nih.gov/35209140/
  6. Wang H, Zhu C, Ying Y, Luo L, Huang D, Luo Z. Metformin and berberine, Two Versatile Drugs in Treatment of Common Metabolic Diseases. Oncotarget. 2017 Sep 11;9(11):10135–46.
  7. Wang L, Liu D, Wei G, Ge H. Berberine and Metformin in the Treatment of Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Clinical Trials. Health. 2021;13(11):1314–29.
  8. Nazari A, Zahra Rostami Ghotbabadi, Kimia Sadat Kazemi, Yalda Metghalchi, Tavakoli R, Razieh Ziaei Rahimabadi, et al. The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-Analysis of Randomized Controlled Trials. Clinical Therapeutics. 2023 Nov 1;
  9. Lei L, Wang B, Zhao L, Li J, Yan X, Jiang J, et al. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD. JAMA Network Open [Internet]. 2026 Jan 16 [cited 2026 Feb 21];9(1):e2554152–2. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2844037
  10. gov. 2026 [cited 2026 Feb 21]. Available from: https://clinicaltrials.gov/study/NCT03976336
  11. gov. 2026 [cited 2026 Feb 21]. Available from: https://clinicaltrials.gov/study/NCT05105321
  12. gov. 2026 [cited 2026 Feb 21]. Available from: https://clinicaltrials.gov/study/NCT05749874?cond=diabetes
  13. Jang J, Jung Y, Seo SJ, Kim SM, Shim YJ, Cho SH, et al. Berberine activates AMPK to suppress proteolytic processing, nuclear translocation and target DNA binding of SREBP-1c in 3T3-L1 adipocytes. Molecular Medicine Reports. 2017 Apr 26;15(6):4139–47.
  14. Kong Y, Yang H, Nie R, Zhang X, Zhang H, Xin Nian. Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence. European journal of medical research. 2025 Jun 12;30(1).
  15. Turner N, Li JY, Gosby A, To SWC, Cheng Z, Miyoshi H, et al. Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I: A Mechanism for the Action of Berberine to Activate AMP-Activated Protein Kinase and Improve Insulin Action. Diabetes [Internet]. 2008 May 1 [cited 2021 Apr 7];57(5):1414–8. Available from: https://diabetes.diabetesjournals.org/content/57/5/1414.short
  16. Liu YF, Wang HH, Geng YH, Han L, Tu SH, Wang H. Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism. Frontiers in Pharmacology. 2023 Feb 6;14.
  17. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States. Diabetes [Internet]. 2006 Aug 1;55(8):2256–64. Available from: https://diabetes.diabetesjournals.org/content/55/8/2256
  18. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action | Garvan Institute of Medical Research [Internet]. Garvan Institute of Medical Research. 2026 [cited 2026 Feb 21]. Available from: https://publications.garvan.org.au/research/publications/2397
  19. Li W, Hua B, Saud SM, Lin H, Hou W, Matter MS, et al. Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. Molecular Carcinogenesis. 2014 May 17;54(10):1096–109.
  20. Zheng Y, Kou J, Wang P, Ye T, Wang Z, Gao Z, et al. Berberine-induced TFEB deacetylation by SIRT1 promotes autophagy in peritoneal macrophages. Aging [Internet]. 2021 Feb 26 [cited 2026 Feb 21];13(5):7096–119. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7993719/
  21. Xiao Y, Zhang L, Zhou H, Cui Y, Chen K, Zhang H, et al. Berberine extends healthspan and delays neurodegenerative diseases in Caenorhabditis elegans through ROS-dependent PMK-1/SKN-1 activation. Archives of Gerontology and Geriatrics [Internet]. 2024 Sep 26;128:105644. Available from: https://www.sciencedirect.com/science/article/pii/S0167494324003200
  22. Lin X, Zhang N. Berberine: Pathways to protect neurons. Phytotherapy Research. 2018 May 6;32(8):1501–10.
  23. Song T, Wei Da Chen. Berberine inhibited carotid atherosclerosis through PI3K/AKTmTOR signaling pathway. Bioengineered. 2021 Jan 1;12(1):8135–46.
  24. DiNicolantonio JJ, McCarty MF, Assanga SI, Lujan LL, O’Keefe JH. Ferulic acid and berberine, via Sirt1 and AMPK, may act as cell cleansing promoters of healthy longevity. Open Heart. 2022 Mar;9(1):e001801.
  25. Elahi Vahed I, Shahir-Roudi E, Nojumi S, Golmohammadi S, Moradi Shahrebabak M, Sharafi Tafreshi Moghadam N, et al. The effect of berberine on obesity indices: a systematic review and meta-analysis. International journal of obesity (2005) [Internet]. 2026 Jan;50(1):53–73. Available from: https://pubmed.ncbi.nlm.nih.gov/41310257/
  26. Shi L, Wang W, Jing C, Hu J, Liao X. Berberine and health outcomes: an overview of systematic reviews. BMC Complementary Medicine and Therapies. 2025 Apr 23;25(1).
  27. Li Z, Wang Y, Xu Q, Ma J, Li X, Yan J, et al. Berberine and health outcomes: An umbrella review. Phytotherapy research: PTR [Internet]. 2023 May 1;37(5):2051–66. Available from: https://pubmed.ncbi.nlm.nih.gov/36999891/
  28. Guo Y, Pope C, Cheng X, Zhou HH, Klaassen CD. Dose–response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. Journal of Ethnopharmacology. 2011 Oct 1;138(1):111–8
  29. Wei-liang L. Study of the effects of Berberine on CYP3A4 and P-gp in HepG2 cells and its mechanism in vitro. Chinese Journal of Clinical Pharmacology and Therapeutics [Internet]. 2020 [cited 2026 Feb 21];20(1):7. Available from: https://manu41.magtech.com.cn/Jweb_clyl/EN/Y2015/V20/I1/7
  30. Nie Q, Li M, Huang C, Yuan Y, Liang Q, Ma X, et al. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. Journal of Translational Medicine. 2024 Mar 1;22(1).
  31. Koperska A, Miller-Kasprzak E, Seraszek-Jaros A, Musialik K, Bogdański P, Szulińska M. The Influence of Berberine on Vascular Function Parameters, Among Them VEGF, in Individuals with MAFLD: A Double-Blind, Randomized, Placebo-Controlled Trial. Nutrients [Internet]. 2025 Winter;17(22):3585. Available from: https://pubmed.ncbi.nlm.nih.gov/41305635/
  32. Chen YX, Gao QY, Zou TH, Wang BM, Liu SD, Sheng JQ, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. The Lancet Gastroenterology & Hepatology [Internet]. 2020 Jan [cited 2020 Jan 15]; Available from: https://www.thelancet.com/pdfs/journals/langas/PIIS2468-1253(19)30409-1.pdf
  33. Health E. Eureka Health [Internet]. Eureka Health. 2025 [cited 2026 Feb 21]. Available from: https://www.eurekahealth.com/resources/berberine-1500mg-weight-loss-like-metformin-results-en
  34. Shomali M, Kumbara A, MacLeod J, Iyer A. Personalized cardiometabolic care powered by artificial intelligence. Frontiers in Endocrinology. 2025 May 23;16.
  35. Utami AR, Maksum IP, Deawati Y. Berberine and Its Study as an Antidiabetic Compound. Biology [Internet]. 2023 Jul 1;12(7):973. Available from: https://www.mdpi.com/2079-7737/12/7/973#:~:text=Several studies have reviewed the
  36. Kant R, Antony MA, Geurkink D, Gilreath N, Chandra L, Zipprer E, et al. Real-time continuous glucose monitoring improves glycemic control and reduces hypoglycemia: Real-world data. Primary Care Diabetes. 2022 Sep;
  37. Seyedi SA, González-Rivas JP, Mellacheruvu P, Mellacheruvu A, Aledavood SP, Esteghamati A, et al. Cardiometabolic risk reduction with digital twinning in patients with type 2 diabetes. Cardiovascular Diabetology – Endocrinology Reports. 2025 Nov 20;11(1).
  38. Su C, Wang P, Foo N, Ho D. Optimizing metabolic health with digital twins. npj Aging. 2025 Mar 24;11(1).
  39. González A, Hall MN, Lin SC, Hardie DG. AMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth Control. Cell Metabolism. 2020 Mar;31(3):472–92.
  40. O’Sullivan S, Qi L, Zalloua P. From omics to AI —mapping the pathogenic pathways in type 2 diabetes. FEBS Letters [Internet]. 2025 Jul 17 [cited 2026 Feb 21];599(22):3244–80. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12643064/
  41. Mosquera-Lopez C, Jacobs PG. Digital twins and artificial intelligence in metabolic disease research. Trends in Endocrinology and Metabolism. 2024 May 13;35(6):549–57.
  42. Chen J, Liu B, Yao X, Yang X, Sun J, Yi J, et al. AMPK/SIRT1/PGC‐1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies From Energy Homeostasis Regulation to Disease Therapy. CNS Neuroscience & Therapeutics [Internet]. 2025 Nov [cited 2025 Nov 29];31(11). Available from: https://pubmed.ncbi.nlm.nih.gov/41268687

‌

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading